ABSTRACT
Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Anti-diabetic, hypolipidemic and anti-oxidative properties of ginger have been noticed in several researches. The present study was conducted to investigate the effects of ginger on fasting blood sugar, Hemoglobin A1c, apolipoprotein B, apolipoprotein A-I, and malondialdehyde in type 2 diabetic patients. In a randomized, double-blind, placebo-controlled, clinical trial, a total of 41 type 2 diabetic patients randomly were assigned to ginger or placebo groups [22 in ginger group and 19 in control group], received 2 g/day of ginger powder supplement or lactose as placebo for 12 weeks. The serum concentrations of fasting blood sugar, Hemoglobin A1c, apolipoprotein B, apolipoprotein A-I and malondialdehyde were analyzed before and after the intervention. Ginger supplementation significantly reduced the levels of fasting blood sugar, hemoglobin A1c, apolipoprotein B, apolipoprotein B/apolipoprotein A-I and malondialdehyde in ginger group in comparison to baseline, as well as control group, while it increased the level of apolipoprotein A-I [p<0.05]. It seems that oral administration of ginger powder supplement can improves fasting blood sugar, hemoglobin A1c, apolipoprotein B, apolipoprotein A-I, apolipoprotein B/apolipoprotein A-I and malondialdehyde in type 2 diabetic patients. So it may have a role in alleviating the risk of some chronic complications of diabetes
Subject(s)
Humans , Female , Male , Blood Glucose , Fasting , Glycated Hemoglobin , Apolipoproteins B , Apolipoprotein A-I , Malondialdehyde , Diabetes Mellitus, Type 2 , Double-Blind MethodABSTRACT
Sumac Rhuscoriaria L. is used as an herbal remedy in traditional medicine. The aim of this study was to determine the effects of sumac [R. coriaria] on serum glycemic status, apolipoprotein [apo] B, apoA-I and total antioxidant capacity [TAC] in type 2 diabetic patients. This double blind randomized controlled clinical trial was conducted on 41type 2 diabetic volunteers randomly assigned into 3g/day sumac powder [n=22] or placebo [n=19] groups over 3 months. Blood samples were collected before and after the intervention. Serum glucose and HbA1c were measured using enzymatic and turbidimetric inhibition immunoassay methods, respectively. ApoB, apoA-I and TAC were determined using turbidimetric immunoassay and spectrophotometric methods, respectively. There were significant decreases in serum glucose and HbA1c and als oapoB levels at the end of study compared with initial values [P< 0.0001, P= 0.002 and P< 0.0001, respectively]. Also, there was a significant difference in HbA1c and TAC levels between placebo and sumac groups at the end of study [P< 0.05]. In sumac group, there were significant increase in apoA-I and TAC [P< 0.0001] compared with initial values. The mean of differences of serum glucose, HbA1c, apoB, apoA-I, apoB/apoA-I ratio and TAC between groups were significant [P< 0.05]. In conclusion, these results showed the favorite effect of sumac consumption on serum glycemic status, apoB, apoA-I and TAC levels in in type 2 diabetic patients